Efficacy and Safety of NYX-2925 in Subjects With Fibromyalgia
NCT ID: NCT04147858
Last Updated: 2023-04-28
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
310 participants
INTERVENTIONAL
2019-11-12
2022-06-16
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluate the Efficacy and Safety of NYX-2925 in Subjects With Fibromyalgia
NCT03249103
Trial Comparing the Effects of Xyrem (Sodium Oxybate) With Placebo for the Treatment of Fibromyalgia
NCT00087555
A Trial Assessing The Effectiveness and Safety of [S,S]-Reboxetine in Patients With Fibromyalgia
NCT00357825
Duloxetine Versus Placebo in the Treatment of FMS
NCT00233025
A 14-week, Multi-center Study of [S,S]-Reboxetine in Patients With Fibromyalgia.
NCT00612170
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This 13- to 16-week study will include a 1- to 4-week Screening Period followed by a 12-week double-blind, randomized, placebo-controlled Treatment Period.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
NYX-2925 50 mg
NYX-2925 50 mg administered orally.
NYX-2925
NYX-2925 administered orally
NYX-2925 100 mg
NYX-2925 100 mg administered orally.
NYX-2925
NYX-2925 administered orally
Placebo
Placebo administered orally.
Placebo
Placebo administered orally
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
NYX-2925
NYX-2925 administered orally
Placebo
Placebo administered orally
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subject has a history of fibromyalgia that was diagnosed \>1 year prior to screening and reports at least moderate pain over the last week
* Stable protocol allowed medication and other therapies during the study
* Agrees to use highly effective birth control during the study
* Has not participated in an interventional study for at least 30 days and agrees not to participate in another interventional study during the study
Exclusion Criteria
* Current or historical serious medical conditions
* Prior participation in NYX-2925 clinical trial
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Worldwide Clinical Trials
OTHER
Aptinyx
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Aptinyx Clinical Site
Phoenix, Arizona, United States
Aptinyx Clinical Site
Culver City, California, United States
Aptinyx Clinical Site
Fresno, California, United States
Aptinyx Clinical Site
Orange, California, United States
Aptinyx Clinical Site
Redlands, California, United States
Aptinyx Clinical Site
Temecula, California, United States
Aptinyx Clinical Site
Torrance, California, United States
Aptinyx Clinical Site
Fernandina Beach, Florida, United States
Aptinyx Clinical Site
Jacksonville, Florida, United States
Aptinyx Clinical Site
Jacksonville, Florida, United States
Aptinyx Clinical Site
Lady Lake, Florida, United States
Aptinyx Clinical Site
Miami, Florida, United States
Aptinyx Clinical Site
Orlando, Florida, United States
Aptinyx Clinical Site
Palmetto Bay, Florida, United States
Aptinyx Clinical Site
Winter Park, Florida, United States
Aptinyx Clinical Site
Alpharetta, Georgia, United States
Aptinyx Clinical Site
Chicago, Illinois, United States
Aptinyx Clinical Site
Flossmoor, Illinois, United States
Aptinyx Clinical Site
Gurnee, Illinois, United States
Aptinyx Clinical Site
Skokie, Illinois, United States
Aptinyx Clinical Site
Evansville, Indiana, United States
Aptinyx Clinical Site
West Des Moines, Iowa, United States
Aptinyx Clinical Site
Newton, Kansas, United States
Aptinyx Clinical Site
Prairie Village, Kansas, United States
Aptinyx Clinical Site
Wichita, Kansas, United States
Aptinyx Clinical Site
Roslindale, Massachusetts, United States
Aptinyx Clinical Site
Hazelwood, Missouri, United States
Aptinyx Clinical Site
Omaha, Nebraska, United States
Aptinyx Clinical Site
Las Vegas, Nevada, United States
Aptinyx Clinical Site
Brooklyn, New York, United States
Aptinyx Clinical Site
New York, New York, United States
Aptinyx Clinical Site
New York, New York, United States
Aptinyx Clinical Site
Staten Island, New York, United States
Aptinyx Clinical Site
Williamsville, New York, United States
Aptinyx Clinical Site
Cincinnati, Ohio, United States
Aptinyx Clinical Site
Oklahoma City, Oklahoma, United States
Aptinyx Clinical Site
Duncansville, Pennsylvania, United States
Aptinyx Clinical Site
Memphis, Tennessee, United States
Aptinyx Clinical Site
Austin, Texas, United States
Aptinyx Clinical Site
Houston, Texas, United States
Aptinyx Clinical Site
Danville, Virginia, United States
Aptinyx Clinical Site
Bellevue, Washington, United States
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol
Document Type: Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NYX-2925-2005
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.